DK123240B - Analogifremgangsmåde til fremstilling af 1,4-disubstituerede piperazin- og diazepinderivater samt syreadditionssalte heraf. - Google Patents

Analogifremgangsmåde til fremstilling af 1,4-disubstituerede piperazin- og diazepinderivater samt syreadditionssalte heraf.

Info

Publication number
DK123240B
DK123240B DK288065AA DK288065A DK123240B DK 123240 B DK123240 B DK 123240B DK 288065A A DK288065A A DK 288065AA DK 288065 A DK288065 A DK 288065A DK 123240 B DK123240 B DK 123240B
Authority
DK
Denmark
Prior art keywords
preparation
acid addition
addition salts
analogous process
diazepine derivatives
Prior art date
Application number
DK288065AA
Other languages
Danish (da)
English (en)
Inventor
H Hermans
W Schaper
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of DK123240B publication Critical patent/DK123240B/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/067—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • D—TEXTILES; PAPER
    • D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
    • D21J—FIBREBOARD; MANUFACTURE OF ARTICLES FROM CELLULOSIC FIBROUS SUSPENSIONS OR FROM PAPIER-MACHE
    • D21J7/00—Manufacture of hollow articles from fibre suspensions or papier-mâché by deposition of fibres in or on a wire-net mould

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Manufacturing & Machinery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK288065AA 1964-06-09 1965-06-09 Analogifremgangsmåde til fremstilling af 1,4-disubstituerede piperazin- og diazepinderivater samt syreadditionssalte heraf. DK123240B (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37384064A 1964-06-09 1964-06-09
US455973A US3267104A (en) 1964-06-09 1965-05-14 1, 4-disubstituted piperazines and diazepines

Publications (1)

Publication Number Publication Date
DK123240B true DK123240B (da) 1972-05-29

Family

ID=27006331

Family Applications (1)

Application Number Title Priority Date Filing Date
DK288065AA DK123240B (da) 1964-06-09 1965-06-09 Analogifremgangsmåde til fremstilling af 1,4-disubstituerede piperazin- og diazepinderivater samt syreadditionssalte heraf.

Country Status (12)

Country Link
US (1) US3267104A (enExample)
BE (1) BE664940A (enExample)
BR (1) BR6570272D0 (enExample)
CH (1) CH456606A (enExample)
DE (1) DE1570001C3 (enExample)
DK (1) DK123240B (enExample)
FI (1) FI47369C (enExample)
FR (2) FR1466269A (enExample)
GB (1) GB1055100A (enExample)
NL (2) NL6507312A (enExample)
NO (1) NO118219B (enExample)
SE (1) SE342820B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308387A (en) * 1978-10-20 1981-12-29 Ab Ferrosan Diphenylbutyl-piperzinecarboxamides

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3679686A (en) * 1970-09-09 1972-07-25 Janssen Pharmaceutica Nv N-(bicycloamino-alkanoyl)-anilines
US3953448A (en) * 1972-12-07 1976-04-27 Delmar Chemicals Limited Piperazino-anilido compounds
DE2304154A1 (de) * 1973-01-29 1974-08-01 Ichthyol Ges Cordes Hermanni & Verfahren zur herstellung von substituierten piperazin- bzw. homopiperazinderivaten
US4260760A (en) * 1975-09-02 1981-04-07 Merck & Co., Inc. Diaryl-aliphatic-amino-aliphatic-piperazines
US4492698A (en) * 1980-06-16 1985-01-08 Bjoerk Anders K Diphenylbutyl-1-acylpiperazines
NO155805C (no) * 1981-02-06 1987-06-10 Ucb Sa Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(4-(difenylmethyl)-1-piperazinyl)-eddiksyrer og deres amider og ikke-toksiske salter.
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
IT1190375B (it) * 1985-06-20 1988-02-16 Recordati Chem Pharm N-benzidrildiazacicloalchil-alcanilidi ad attivita' antianafilattica ed antibroncospastica
DE3600390A1 (de) * 1986-01-09 1987-07-16 Hoechst Ag Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel
US4880808A (en) * 1987-04-01 1989-11-14 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for improving sleep
US5026853A (en) * 1987-04-01 1991-06-25 Janssen Pharmaceutica N.V. 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
FR2614021B1 (fr) * 1987-04-14 1991-03-01 Andre Buzas Derives de la 1-((1,1-diphenyl)-1-alcenyl)-piperazine, procede d'obtention et compositions pharmaceutiques les contenant
ES2046107B1 (es) * 1992-03-05 1994-08-01 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados de la difenilmetilpiperacina.
ATE174913T1 (de) * 1992-07-31 1999-01-15 Bristol Myers Squibb Co Diphenyl oxazole-, thiazole- und imidazole- derivate als inhibitoren der wiederaufnahme des adenosins
EP0690051B1 (en) * 1994-01-14 2001-07-18 Azwell Inc. Diazacycloalkanealkylsulfonamide derivative
CA2204355C (en) 1994-11-02 2001-01-16 Gail Mandel Peripheral nervous system specific sodium channels, dna encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
US6441172B1 (en) * 1996-11-07 2002-08-27 Torrey Pines Institute For Molecular Studies Diketodiazacyclic compounds, diazacyclic compounds and combinatorial libraries thereof
CA2234342A1 (en) * 1997-04-10 1998-10-10 Kyowa Hakko Kogyo Co., Ltd. Pancreatitis remedy
CO5040088A1 (es) 1998-04-03 2001-05-29 Advanced Medicine Inc Nuevos compuestos y usos anestesicos locales
US6462034B1 (en) 1998-04-03 2002-10-08 Theravance, Inc. Local anesthetic compounds and uses
US6268377B1 (en) 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
KR20070120617A (ko) * 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
IL156445A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
TW200840563A (en) * 2001-01-26 2008-10-16 Schering Corp Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
PT1363668E (pt) * 2001-01-26 2007-11-07 Schering Corp Combinaçoes de sequestrante(s) de ácidos biliares e inibidor(es) de absorção de esterol e tratamento de indicações vasculares
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EP1385548B1 (en) * 2001-01-26 2007-05-23 Schering Corporation Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
NZ542090A (en) * 2001-01-26 2006-09-29 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
WO2002096415A2 (en) * 2001-05-25 2002-12-05 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
EP1429756B1 (en) * 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
DE60229406D1 (de) * 2001-09-21 2008-11-27 Schering Corp Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
EA200500234A1 (ru) 2002-08-19 2005-08-25 Пфайзер Продактс Инк. Комбинированная терапия гиперпролиферативных болезней
CA2504916A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081004A1 (en) * 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004093813A2 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
US20050159403A1 (en) * 2003-04-22 2005-07-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
WO2005046797A2 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
CA2574958A1 (en) * 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
WO2007050783A2 (en) 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308387A (en) * 1978-10-20 1981-12-29 Ab Ferrosan Diphenylbutyl-piperzinecarboxamides

Also Published As

Publication number Publication date
FR4897M (enExample) 1967-03-13
NL6507312A (enExample) 1965-12-10
SE342820B (enExample) 1972-02-21
BR6570272D0 (pt) 1973-09-06
FR1466269A (fr) 1967-01-20
FI47369C (fi) 1973-11-12
US3267104A (en) 1966-08-16
DE1570001C3 (de) 1975-04-10
CH456606A (fr) 1968-07-31
DE1570001B2 (de) 1974-08-22
NL137318C (enExample)
BE664940A (enExample) 1965-12-06
GB1055100A (en) 1967-01-11
NO118219B (enExample) 1969-12-01
DE1570001A1 (de) 1970-02-19
FI47369B (enExample) 1973-07-31

Similar Documents

Publication Publication Date Title
DK105984C (da) Fremgangsmåde til fremstilling af 1,5-disubstituerede 1,4-benzodiazepinderivater eller syreadditionssalte deraf.
DK116441B (da) Fremgangsmåde til fremstilling af 10,11-dihydro-dibenzo-(b,f)-thiepinderivater.
DK120548B (da) Fremgangsmåde til fremstilling af 1,4-benzodiazepinderivater eller 4-oxider eller syreadditionssalte deraf.
DK135043B (da) Analogifremgangsmåde til fremstilling af i 5-stillingen substituerede 5,10-dihydro-11H-dibenzo(b,e) (1,4) diazepin-11-oner samt syreadditionssalte deraf.
DK116363B (da) Fremgangsmåde til fremstilling af N,N'-disubstituerede piperazinderivater.
DK115851B (da) Fremgangsmåde til fremstilling af 1,2-dihydro-4-aryl-quinazoliner eller syreadditionssalte deraf.
DK121367B (da) Analogifremgangsmåde til fremstilling af 3,3-difenylallylaminderivater eller syreadditionssalte deraf.
DK118663B (da) Analogifremgangsmåde til fremstilling af basisk substituerede derivater af 5,6-dihydro-dibenz-[b,e]-azepin-6, 11-dion-11-oxim eller syreadditionssalte deraf.
DK108921C (da) Fremgangsmåde til fremstilling af tetrahydro-1,3,5-thiadiazin-2-thioner.
DK118290B (da) Analogifremgangsmåde til fremstilling af basisk substituerede naphthalen-(1,4,5,8)-tetracarboxylsyre-diimider eller salte deraf.
DK138740B (da) Fremgangsmåde til fremstilling af 1,4-benzodiazepinderivater eller syreadditionssalte deraf.
DK112317B (da) Fremgangsmåde til fremstilling af piperazin- eller homopiperazinforbindelser eller syreadditionssalte deraf.
DK118668B (da) Fremgangsmåde til fremstilling af tetrahydro-1,3,5-thiadiazin-2-thioner eller syreadditionssalte deraf.
DK121125B (da) Fremgangsmåde til fremstilling af 1,4-benzodiazepinderivater eller syreadditionssalte deraf.
DK119505B (da) Analogifremgangsmåde til fremstilling af s-triazolo[3,4-a]isoquinoliner eller syreadditionssalte deraf.
DK118657B (da) Analogifremgangsmåde til fremstilling af 3',4',5'-trimethoxy-3-aminoacrylophenoner eller syreadditionssalte deraf.
DK135311B (da) Fremgangsmåde til fremstilling af 1,4-benzodiazepinderivater eller syreadditionssalte deraf.
DK116215B (da) Analogifremgangsmåde til fremstilling af 1,4-bis-substituerede piperazin-derivater.
DK108975C (da) Fremgangsmåde til fremstilling af piperazinsalte.
DK104408C (da) Fremgangsmåde til fremstilling af 5-aryl-3H-1,4-benzodiazepinderivater eller syreadditionssalte deraf.
DK119705B (da) Fremgangsmåde til fremstilling af 4,5-disubstituerede 2-alkyl-3-hydroxy-pyridiner eller syreadditionssalte deraf.
DK107227C (da) Fremgangsmåde til fremstilling af 3,8-diazabicyklooktanderivater af fentiaziner, eller syreadditionssalte deraf.
DK135841B (da) Fremgangsmåde til fremstilling af 1,3,4,5-tetrahydro-5-phenyl-2H-1,4-benzodiazepin-2-on-derivater eller syreadditionssalte deraf.
DK114776B (da) Analogifremgangsmåde til fremstilling af 3-(2-fluorphenyl)-1,2,3-benzotriazin-4-on eller syreadditionssalte heraf.
DK119313B (da) Fremgangsmåde til fremstilling af 3-hydrazino-1,2,8,9-tetraazaphenalener eller syreaaditionssalte deraf.